Hypercalcemia

Hypercalcemia is a metabolic disorder characterized by serum calcium concentrations above the upper limit of normal (>10.5 mg/dL or >2.62 mmol/L; ionized calcium >1.35 mmol/L). It disrupts cellular function across multiple organ systems, most notably the cardiac, renal, gastrointestinal, and central nervous systems.

• Primary Hyperparathyroidism (PHPT): The most common outpatient cause, typically due to a solitary parathyroid adenoma or multiglandular hyperplasia.
• Malignancy: The most common inpatient cause, mediated by PTH-related peptide (PTHrP) secretion (squamous, renal cell cancers), osteolytic bone metastases (multiple myeloma, breast cancer), or extrarenal calcitriol synthesis (lymphoma).
• Granulomatous Diseases: Sarcoidosis and tuberculosis, driven by unregulated extrarenal 1-alpha-hydroxylase activity converting vitamin D to active calcitriol.
• Medications: Thiazide diuretics (decreased renal calcium excretion), lithium (shifts PTH set-point), and excessive calcium/vitamin D supplementation (milk-alkali syndrome).

Hypercalcemia occurs when calcium influx into the extracellular fluid (via osteoclastic bone resorption, intestinal absorption, or renal reabsorption) outpaces renal clearance. Normally, parathyroid hormone (PTH) and calcitriol maintain tight calcium homeostasis. High extracellular calcium activates calcium-sensing receptors (CaSR) in the kidney, which impairs renal concentrating mechanisms (causing nephrogenic diabetes insipidus) and triggers afferent arteriolar vasoconstriction, lowering the glomerular filtration rate (GFR).

• Prevalence: Affects approximately 1% to 2% of the general population; prevalence rises to nearly 3% in hospitalized patients.
• Age and Gender: Most common in postmenopausal women, with a female-to-male ratio of 3:1. The peak incidence for PHPT occurs between 50 and 60 years of age.

• Postmenopausal status
• History of neck irradiation
• Chronic lithium or thiazide diuretic therapy
• Prolonged immobilization
• Granulomatous or granulomatous-like diseases (e.g., sarcoidosis)

• Vital Signs: Hypertension, bradycardia.
• Neuromuscular: Hypotonia, hyporeflexia, cognitive delay, and confusion.
• Ophthalmologic: Band keratopathy (calcium phosphate deposits on the cornea).
• Gastrointestinal: Generalized abdominal tenderness (secondary to constipation or acute pancreatitis).

• A. Clinical Assessment: Comprehensive history focusing on medications, supplements, systemic symptoms, and family history.
• B. Laboratory Testing: Initial screening must include serum total calcium, albumin, ionized calcium, and intact PTH (iPTH).
• C. Imaging Studies: Sestamibi scan for parathyroid localization; dual-energy X-ray absorptiometry (DXA) to assess bone density.
• D. Functional Tests: 24-hour urine calcium and creatinine clearance.
• E. Biopsy Findings: Bone biopsy (rarely required) showing accelerated osteoclastic bone resorption; parathyroid biopsy indicating adenoma or hyperplasia.

• G. Differential Diagnosis: Differentiating PTH-mediated (high/normal PTH) from non-PTH-mediated (suppressed PTH) hypercalcemia.

Serum Total Calcium
Type: Blood Test
Purpose: Screen for and confirm elevated systemic calcium levels.
Expected Findings: >10.5 mg/dL (>2.62 mmol/L).
Interpretation: Elevated; must adjust for low albumin levels using the formula: Corrected Calcium = Total Calcium + [0.8 × (4.0 - Albumin)]. Intact PTH (iPTH)
Type: Blood Test
Purpose: Differentiate PTH-mediated causes from non-PTH-mediated causes.
Expected Findings: Elevated or inappropriately normal in PHPT; suppressed (<20 pg/mL) in malignancy and other causes.
Interpretation: High/normal points to PHPT or FHH; low suggests malignancy, vitamin D toxicity, or granulomatous disease. 24-Hour Urine Calcium
Type: Urine Test
Purpose: Differentiate PHPT from FHH.
Expected Findings: >200 mg/day in PHPT; low (<100 mg/day) in FHH.
Interpretation: Calcium-to-creatinine clearance ratio <0.01 indicates FHH; >0.02 indicates PHPT.

• Tc-99m Sestamibi Scintigraphy: High sensitivity for localizing hyperfunctioning parathyroid adenomas prior to surgical intervention.
• Dual-Energy X-ray Absorptiometry (DXA): Evaluates bone mineral density loss; typically shows cortical bone depletion (e.g., distal radius) in primary hyperparathyroidism.
• Renal Ultrasonography: Detects nephrolithiasis, nephrocalcinosis, or structural kidney damage.

• Primary Hyperparathyroidism: High/normal PTH, high calcium, high urinary calcium.
• Malignancy-Associated Hypercalcemia: Suppressed PTH, elevated PTHrP, very high calcium levels.
• Familial Hypocalciuric Hypercalcemia (FHH): High/normal PTH, mild hypercalcemia, low urinary calcium excretion.
• Vitamin D Toxicity: Suppressed PTH, markedly elevated 25-hydroxyvitamin D or 1,25-dihydroxyvitamin D.

• Nephrolithiasis, nephrocalcinosis, and chronic kidney disease.
• Severe osteoporosis and pathologic fractures.
• Cardiac dysrhythmias and vascular calcification.
• Peptic ulcer disease and acute pancreatitis.

• PHPT: Excellent prognosis; parathyroidectomy is curative in over 95% of cases.
• Malignancy-Related: Poor; often indicates advanced, late-stage neoplastic disease with limited survival.

• Routine biochemical monitoring during lithium or thiazide treatment.
• Avoiding high-dose vitamin D and calcium self-supplementation.

The following homeopathic remedies have been historically indicated for symptoms associated with Hypercalcemia. Selection should be based on individualized symptom totality and constitutional assessment.

• Homeopathy by Hadhrat Mirza Tahir Ahmad (r.a.) — Primary clinical reference
• Robin Murphy — Lotus Materia Medica (3rd Edition)
• William Boericke — Pocket Manual of Homœopathic Materia Medica & Repertory
• ICD-10/ICD-11 Classification — World Health Organization
• Harrison's Principles of Internal Medicine (Reference Standard)

This clinical reference profile is compiled from authoritative medical sources for educational purposes. Always verify clinical data with current medical guidelines.

📊 Pulmonary Embolism Rule-Out Criteria (PERC)

Evaluates low-risk patients suspected of pulmonary embolism to safely rule out PE clinically without requiring blood tests or imaging.